Literature DB >> 7931077

A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells.

G Franzoso1, P Biswas, G Poli, L M Carlson, K D Brown, M Tomita-Yamaguchi, A S Fauci, U K Siebenlist.   

Abstract

Two groups of U937 promonocytic cells were obtained by limiting dilution cloning which differed strikingly in their ability to support human immunodeficiency virus 1 (HIV-1) replication. "Plus" clones replicated the virus efficiently, whereas "minus" clones did not. We examined these clones for differences in nuclear factor (NF)-kappa B activity which might account for the observed phenomenon. Stimulation of plus clones liberated the classical p50-p65 complex from cytoplasmic pools, whereas minus clones produced an apparently novel, faster-migrating complex, as judged by electrophoretic mobility shift assays. It is surprising that the faster-migrating complex was composed also of p50 and p65. However, the p65 subunit was COOH-terminally truncated, as shown by immunoprecipitation. The truncation resulted from limited proteolysis of p65 during cellular extraction which released particular lysosomal serine proteases, such as elastase, cathepsin G, and proteinase 3. These specific proteases are coordinately expressed and were present exclusively in the minus U937 clones, but not in the plus clones, as demonstrated in the case of cathepsin G. In addition, these proteases were detected in certain subclones of THP-1 and HL-60 cells and in primary monocytes, in each case correlating with the truncated from of p65. We demonstrate in vitro cleavage of p65 by purified elastase and cathepsin G. It is possible that particular serine proteases may have inhibiting effects on the replication of HIV-1 in myelo-monocytic cells. The data also demonstrate that special precautions must be taken when making extracts from myelo-monocytic cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7931077      PMCID: PMC2191703          DOI: 10.1084/jem.180.4.1445

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  69 in total

Review 1.  NF-kappa B and Rel: participants in a multiform transcriptional regulatory system.

Authors:  M Grilli; J J Chiu; M J Lenardo
Journal:  Int Rev Cytol       Date:  1993

2.  Autoregulation of I kappa B alpha activity.

Authors:  P J Chiao; S Miyamoto; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

3.  NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway.

Authors:  S C Sun; P A Ganchi; D W Ballard; W C Greene
Journal:  Science       Date:  1993-03-26       Impact factor: 47.728

Review 4.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.

Authors:  J Embretson; M Zupancic; J L Ribas; A Burke; P Racz; K Tenner-Racz; A T Haase
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

6.  Negative regulation of human immune deficiency virus replication in monocytes. Distinctions between restricted and latent expression in THP-1 cells.

Authors:  J A Mikovits; M Gonda; M Ruta; N C Lohrey; H F Kung; F W Ruscetti
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

7.  Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist.

Authors:  G Poli; A L Kinter; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

Review 8.  Antibiotic peptides and serine protease homologs in human polymorphonuclear leukocytes: defensins and azurocidin.

Authors:  J E Gabay; R P Almeida
Journal:  Curr Opin Immunol       Date:  1993-02       Impact factor: 7.486

9.  The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers.

Authors:  V Bours; G Franzoso; V Azarenko; S Park; T Kanno; K Brown; U Siebenlist
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

10.  Cytokine-mediated induction of human immunodeficiency virus (HIV) expression and cell death in chronically infected U1 cells: do tumor necrosis factor alpha and gamma interferon selectively kill HIV-infected cells?

Authors:  P Biswas; G Poli; J M Orenstein; A S Fauci
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  26 in total

1.  Phosphorylation of NF-kappaB p65 at Ser468 controls its COMMD1-dependent ubiquitination and target gene-specific proteasomal elimination.

Authors:  Hui Geng; Tobias Wittwer; Oliver Dittrich-Breiholz; Michael Kracht; Michael Lienhard Schmitz
Journal:  EMBO Rep       Date:  2009-03-06       Impact factor: 8.807

2.  Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.

Authors:  Giovanna Tosi; Greta Forlani; Vibeke Andresen; Marco Turci; Umberto Bertazzoni; Genoveffa Franchini; Guido Poli; Roberto S Accolla
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  Constitutive expression of p50 homodimer in freshly isolated human monocytes decreases with in vitro and in vivo differentiation: a possible mechanism influencing human immunodeficiency virus replication in monocytes and mature macrophages.

Authors:  S R Lewin; P Lambert; N J Deacon; J Mills; S M Crowe
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Internalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidants.

Authors:  J J Yang; G A Preston; W F Pendergraft; M Segelmark; P Heeringa; S L Hogan; J C Jennette; R J Falk
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

5.  TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements.

Authors:  Anna Kajaste-Rudnitski; Sara S Marelli; Cinzia Pultrone; Thomas Pertel; Pradeep D Uchil; Nadir Mechti; Walther Mothes; Guido Poli; Jeremy Luban; Elisa Vicenzi
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

6.  Promonocytic U937 subclones expressing CD4 and CXCR4 are resistant to infection with and cell-to-cell fusion by T-cell-tropic human immunodeficiency virus type 1.

Authors:  H Moriuchi; M Moriuchi; J Arthos; J Hoxie; A S Fauci
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

7.  Chronic human immunodeficiency virus type 1 infection of myeloid cells disrupts the autoregulatory control of the NF-kappaB/Rel pathway via enhanced IkappaBalpha degradation.

Authors:  C DeLuca; A Roulston; A Koromilas; M A Wainberg; J Hiscott
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  1,25-Dihydroxyvitamin D3 upregulates functional CXCR4 human immunodeficiency virus type 1 coreceptors in U937 minus clones: NF-kappaB-independent enhancement of viral replication.

Authors:  P Biswas; M Mengozzi; B Mantelli; F Delfanti; A Brambilla; E Vicenzi; G Poli
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

9.  Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication.

Authors:  Massimo Alfano; Nicolai Sidenius; Barbara Panzeri; Francesco Blasi; Guido Poli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

10.  Rhinovirus stimulation of interleukin-6 in vivo and in vitro. Evidence for nuclear factor kappa B-dependent transcriptional activation.

Authors:  Z Zhu; W Tang; A Ray; Y Wu; O Einarsson; M L Landry; J Gwaltney; J A Elias
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.